NASDAQ:ABVX 20 November 2025

Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax S.A. is set for a lagged Paris opening after its U.S. ADS jumped in after-hours trading. Investors reacted to new clinical data on obefazimod, Abivax’s ulcerative colitis drug. The latest news hits late, but the drop earlier this month wasn’t about whether the drug works. It was about the potential cancer risk and what that could mean for the drug’s label.

30 June 2026

Biotechnology·EPA:ABVX·NASDAQ:ABVX·Stock Market

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares tumbled in late U.S. trading on Monday, despite the French biotech putting out positive late-stage results for its main ulcerative colitis drug. The American depositary shares were at $86.01 after hours, a drop of 33.7% from their regular close at $129.69, according to Google Finance.

2 June 2026

Biotechnology·EPA:ABVX·NASDAQ:ABVX·Stock Market

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares.

7 January 2026

Nasdaq·NASDAQ:ABVX·Stock Market

Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

Abivax shares fell about 9.1% to $121.64 in midday U.S. trading on Monday, after touching $133.73 earlier in the session. The stock hit a low of $121.08, while its Paris-listed shares ended down 9.7%. Investing

5 January 2026

NASDAQ:ABVX·Pharmaceuticals·Stock Market

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax Société Anonyme’s U.S.-listed American depositary shares fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138 and swung between $132.13 and $140.25, with about 348,000 shares traded.

31 December 2025

Mergers and Acquisitions·NASDAQ:ABVX·Pharmaceutical Industry

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025: U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters

26 December 2025

Mergers & Acquisitions·NASDAQ:ABVX·NYSE:LLY·Stock Market

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index, effective before today’s market open. GlobeNewswire+2Investing.com+2

22 December 2025

EPA:ABVX·Mergers and Acquisitions·NASDAQ:ABVX·NYSE:LLY·Stock Market

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

December 16, 2025 — ABIVAX Société Anonyme is back in the spotlight today after publishing third-quarter 2025 financial results and reiterating a long cash runway—news that didn’t stop the stock from pulling back as investors digested widening losses and the sheer scale of the rally already priced in.

16 December 2025

Earnings Reports·EPA:ABVX·Mergers and Acquisitions·NASDAQ:ABVX

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease contender.Reuters+1

10 December 2025

EPA:ABVX.PA·Mergers & Acquisitions·NASDAQ:ABVX·NYSE:LLY·Stock Market

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA, the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca.

20 November 2025

NASDAQ:ABVX·NYSE:AZN·Stock Market

NASDAQ:ABVX 20 November 2025 - 30 June 2026